Profile data is unavailable for this security.
About the company
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.
- Revenue in USD (TTM)167.49m
- Net income in USD-240.46m
- Incorporated1993
- Employees486.00
- LocationFibroGen Inc409 ILLINOIS STREETSAN FRANCISCO 94158United StatesUSA
- Phone+1 (415) 978-1200
- Fax+1 (415) 978-1902
- Websitehttps://www.fibrogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -139.79m | 122.44m | 143.00 | -- | 0.4731 | -- | -- | -2.95 | -2.95 | 0.00 | 3.15 | 0.00 | -- | -- | 0.00 | -46.75 | -37.03 | -49.70 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Sangamo Therapeutics Inc | 18.76m | -328.05m | 123.51m | 405.00 | -- | 2.14 | -- | 6.59 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
| Karyopharm Therapeutics Inc | 140.46m | -146.34m | 123.60m | 325.00 | -- | -- | -- | 0.8799 | -1.28 | -1.28 | 1.22 | -1.45 | 0.5298 | 1.67 | 4.24 | 432,187.70 | -55.19 | -53.02 | -72.56 | -65.85 | 96.08 | 97.18 | -104.18 | -125.15 | 2.99 | -9.66 | 2.25 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| aTyr Pharma Inc | 588.00k | -53.93m | 124.22m | 56.00 | -- | 1.46 | -- | 211.26 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Allakos Inc | 0.00 | -214.44m | 125.73m | 131.00 | -- | 1.20 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| Scpharmaceuticals Inc | 17.63m | -57.71m | 126.55m | 135.00 | -- | 5.15 | -- | 7.18 | -1.49 | -1.49 | 0.4545 | 0.6814 | 0.1713 | 0.7566 | 4.02 | 130,607.40 | -56.07 | -38.23 | -62.13 | -42.31 | 71.69 | -- | -327.29 | -1,360.16 | 5.44 | -16.60 | 0.6159 | -- | -- | -- | -48.79 | -- | -- | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 128.86m | 28.00 | -- | 3.03 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| FibroGen Inc | 167.49m | -240.46m | 129.32m | 486.00 | -- | -- | -- | 0.7721 | -2.45 | -2.45 | 1.70 | -2.29 | 0.3704 | 1.18 | 5.05 | 344,635.80 | -53.71 | -30.62 | -124.24 | -42.31 | 75.46 | 93.52 | -145.02 | -119.08 | 1.27 | -36.51 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Regulus Therapeutics Inc | 0.00 | -31.37m | 132.24m | 28.00 | -- | 1.23 | -- | -- | -1.46 | -1.46 | 0.00 | 1.64 | 0.00 | -- | -- | 0.00 | -41.50 | -53.74 | -45.91 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.005 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 132.43m | 179.00 | -- | 0.566 | -- | 1.35 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 132.84m | 68.00 | -- | 8.82 | -- | 19.03 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Tevogen Bio Holdings Inc | 0.00 | -67.33k | 134.98m | 17.00 | -- | -- | -- | -- | -0.0004 | -0.0004 | 0.00 | -0.0045 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -8.19 | 1.74 | -- | -- | -- | 99.69 | -- | -- | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 136.36m | 120.00 | 8.85 | -- | 7.34 | 1.14 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Vigil Neuroscience Inc | 0.00 | -82.78m | 136.43m | 65.00 | -- | 1.31 | -- | -- | -2.12 | -2.12 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -52.16 | -- | -54.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to FibroGen Inc's reporting currency: US Dollar USD
48.11%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| PRIMECAP Management Co.as of 31 Mar 2024 | 14.42m | 14.60% |
| Armistice Capital LLCas of 31 Mar 2024 | 7.94m | 8.04% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 6.43m | 6.51% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 6.36m | 6.44% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 2.50m | 2.54% |
| Jacobs Levy Equity Management, Inc.as of 31 Mar 2024 | 2.21m | 2.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.16m | 2.19% |
| Geode Capital Management LLCas of 31 Mar 2024 | 2.07m | 2.10% |
| 683 Capital Management LLCas of 31 Mar 2024 | 1.85m | 1.87% |
| Citadel Advisors LLCas of 31 Mar 2024 | 1.57m | 1.59% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
